Recombinant Human Erythropoietin Alfa Injection Franchise in Ahmedabad

Recombinant Human Erythropoietin Alfa Injection Supplier in Mumbai

Recombinant Human Erythropoietin Alfa Injection Distributor in Delhi

Anemia Management Injection Franchise Opportunity in Bangalore

Recombinant Human Erythropoietin Alfa Injection Stockist in Hyderabad
Recombinant Human Erythropoietin Alfa Injection Export & Manufacturing in Chandigarh

Home/Products /recombinant-human-erythropoietin-alfa-10000iu-injection

Recobent 10k Injection

Composition : Recombinant Human Erythropoietin Alfa (10000IU) Injection

Dosage Form : Injection

Packaging Type : Pre-Filled Syringe

Packaging : 1ml

Price : ₹0/-

Please Contact For Best Price

Recobent 10k Injection contains Recombinant Human Erythropoietin Alfa 10000 IU, a biosynthetic hormone used to stimulate red blood cell production. It is widely indicated in anemia associated with chronic kidney disease, chemotherapy-induced anemia, and other conditions involving reduced erythropoiesis.

Recombinant Human Erythropoietin Alfa acts by stimulating bone marrow to increase red blood cell formation, thereby improving hemoglobin levels and reducing the need for blood transfusions. This targeted mechanism supports effective and controlled anemia management.

The injectable formulation ensures rapid bioavailability and predictable therapeutic response, making it suitable for hospital, dialysis center, and specialty care use. Due to its role in long-term anemia treatment, this molecule maintains consistent demand across clinical settings.

Adding Recobent 10k Injection to your injectable and critical care segment strengthens your portfolio with a clinically essential product. Its strong prescriber reliance, institutional usage, and export potential make it a valuable option for pharmaceutical distribution and manufacturing partnerships.

Read More

About the Product

Recobent 10k Injection contains Recombinant Human Erythropoietin Alfa 10000 IU, a biosynthetic hormone used to stimulate red blood cell production. It is widely indicated in anemia associated with chronic kidney disease, chemotherapy-induced anemia, and other conditions involving reduced erythropoiesis.

Recombinant Human Erythropoietin Alfa acts by stimulating bone marrow to increase red blood cell formation, thereby improving hemoglobin levels and reducing the need for blood transfusions. This targeted mechanism supports effective and controlled anemia management.

The injectable formulation ensures rapid bioavailability and predictable therapeutic response, making it suitable for hospital, dialysis center, and specialty care use. Due to its role in long-term anemia treatment, this molecule maintains consistent demand across clinical settings.

Adding Recobent 10k Injection to your injectable and critical care segment strengthens your portfolio with a clinically essential product. Its strong prescriber reliance, institutional usage, and export potential make it a valuable option for pharmaceutical distribution and manufacturing partnerships.

Common side effects may include headache, hypertension, joint pain, fever, nausea, or injection-site reactions. Rare but serious side effects include thromboembolic events or severe allergic reactions. Medical attention is advised if severe or persistent symptoms occur.

Recobent 10K Injection is indicated for the treatment of anemia associated with chronic kidney disease, anemia due to chemotherapy in cancer patients, anemia in patients undergoing zidovudine therapy for HIV, and anemia related to certain chronic disorders, as prescribed by a physician.

Recobent 10K Injection should be administered only under medical supervision. Regular monitoring of hemoglobin levels and blood pressure is essential during therapy. Dose adjustments should be made strictly as per the treating physician’s advice.

Store Recobent 10K Injection in a refrigerator at 2°C–8°C. Do not freeze. Protect from light. Keep out of reach of children and do not use if the solution appears cloudy or discolored.

Get in Touch